tbuckley/cabot-search huggingface dataset:
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
Authors: Jean-Michel Molina, Kathleen Squires, Paul E Sax, Pedro Cahn, Johan Lombaard, Edwin DeJesus, Ming-Tain Lai, Xia Xu, Anthony Rodgers, Lisa Lupinacci, Sushma Kumar, Peter Sklar, Bach-Yen Nguyen, George J Hanna, Carey Hwang, Marcelo Martins, Pedro Enrique Cahn, Gustavo D. Lopardo, Norma Porteiro, Mark Theo Bloch, David Alfred Baker, Norman Roth, Richard James Moore, Robert James Finlayson, James McMahon, Armin Rieger, Alexander Zoufaly, Sylvia Hartl, Robert Zangerle, Fiona Smaill, Sharon L. Walmsley, Brian Conway, Anita Rachlis, Graham H.R. Smith, Carlos Perez, Alejandro Afani, Maria Isabel E. Campos Barker, Carolina Eugenia Chahin, Marcelo Wolff Reyes, Jan Gerstoft, Nina Weis, Alex Lund Laursen, Jean-Michel Molina, Yazdan Yazdanpanah, Laurent Cotte, Francois Raffi, Philippe Morlat, Pierre-Marie Girard, Christine Katlama, Juergen K. Rockstroh, Keikawus Arasteh, Stefan Esser, Albrecht Stoehr, Hans-Juergen Stellbrink, Matthias Stoll, Dirk Schuermann, Gerd Faetkenheuer, Johannes Bogner, Thomas Lutz, Axel Baumgarten, Hans Jaeger, Andrea Gori, Gabriel Coltan, Felicia Constandis, Simona Manuela Erscoiu, Liviu-Jany Prisacariu, Sorin Rugina, Adrian Streinu-Cercel, Vadim Valentinovich Pokrovsky, Natalia V. Zakharova, Andrey Anatolyevich Shuldyakov, Elena Pavlovna Ryamova, Valeriy Viktorovich Kulagin, Olga Aleksandrovna Tsybakova, Elena Orlova-Morozova, Firaya Nagimova, Evgeniy Voronin, Tatyana Evgenyevna Shimonova, Oleg Anatolyevich Kozyrev, Catherine Orrell, Johannes Jurgens Lombaard, Margaretha Elizabeth Botes, Joaquin Portilla, Josep Maria Gatell, Maria Jesus Perez, Jose Ramon Arribas, Eugenia Negredo, Daniel Podzamczer, Federico Pulido, Jesus Troya, Ignacio De los Santos, Juan Berenguer, Ian G. Williams, Margaret A. Johnson, Gabriel Schembri, Amanda Clarke, Mark Gompels, Julie Meriel Fox, Steven John Taylor, Stephen Kegg, Debbie P. Hagins, Olayemi O. Osiyemi, David James Prelutsky, Moti N. Ramgopal, Robin Dretler, Edwin DeJesus, Louis Sloan, Stanley T. Lewis, Patrick G. Clay, Nicholaos C. Bellos, Melanie A. Thompson, Jose Montero, Cheryl K. McDonald, Catherine Creticos, David Shamblaw, Antonio E. Terrelonge, Martin Valdes, Karen T. Tashima, William J. Robbins, Franco Antonio Felizarta, Richard A. Elion, Jihad Slim, Jacob Paul Lalezari, Sujata N. Lalla-Reddy, Peter Jerome Ruane, Anthony Mills, Jerry L. Cade, Rafael E. Campo, Craig A. Dietz, Gary Blick, Cynthia Mayer, Juan Carlos Rondon, Paul P. Cook, Eric Daar, Princy N. Kumar, Susan Swindells, Jose Guillermo Castro, Javier O. Morales-Ramirez, Lizette Santiago, Jorge L. Santana-Bagur
Journal: The Lancet HIV (2018)
Long-term outcome of a randomized phase III trial exploring the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥ T3 resectable gastric cancer: CCOG 1102.
Authors: Daishi Morimoto, Kazunari Misawa, Yoshinari Mochizuki, Mitsuru Sakai, Jin Teramoto, Tsunenobu Takase, Hiroshi Nakayama, Kiyoshi Ishigure, Takanori Matsui, Daisuke Kobayashi, Seiji Ito, Satoshi Morita, Yasuhiro Kodera
Journal: Journal of Clinical Oncology (2018)

1 Background: Extensive intraoperative peritoneal lavage (EIPL) for gastric cancer reportedly improved survival by physically removing and reducing intraperitoneal-free cancer cells in a small-scale randomized trial (Ann Surg 2009). To confirm this, we conducted a multicenter randomized Phase III trial. Methods: Eligibility criteria: (i) histologically confirmed primary gastric adenocarcinoma, (ii) clinically T3(SS), T4a(SE) or T4b(SI), (iii) clinically M0, and (iv) scheduled for total or distal gastrectomy. Patients were intraoperatively randomized to either the EIPL group or the non-EIPL group after confirming the ≥T3 status and resectability. In the EIPL group, peritoneal lavage was conducted at least 10 times using 1L of saline before the closure of the abdomen. In the non-EIPL group, the lavage was conducted with ≤3L of saline. The primary end-point was disease-free survival (DFS). To detect the difference of 15% in 3-year DFS with a both-sided alpha of 5% and 80% power, the planned sample size was 300 cases. This study was registered as UMIN000005907. Results: Between July 2011 and January 2014, 314 patients were registered from 15 institutions. After excluding the R1/R2 resection cases, 295 patients (145 in the EIPL group and 150 in the non-EIPL group) were analyzed. There were no significant differences between the groups in clinicopathologic characteristics. The median volume of saline for the peritoneal lavage was 10.0 L (10 - 12) for the EIPL group and 3.0 L (1 - 4) for the non-EIPL group. No difference was observed in the incidence of postoperative complications. The 3-year DFS was 63.9% in the EIPL group and 59.7% in the non-EIPL group (p = 0.25, Hazard ratio 0.81 [95% CI 0.57-1.16]). The overall survival rate of the EIPL group and non-EIPL group were 75.0%, 73.7% (3 years), and 62.5%, 57.1% (5 years), respectively (p = 0.65). In the subset analysis, no subgroup with significant difference in survival was identified. Conclusions: Although EIPL for advanced gastric cancer was safe and suggested some efficacy, the primary endpoint designed based on the previous small-scale trial was not met. Clinical trial information: 000005907.
What are the requirements to work as a police surgeon?
Authors: Roy Palmer
Journal: BMJ (2004)

<i>Got a career or related problem that needs answering? Can9t find the right person to point you in the right direction? Log on to the Advice Zone (www.bmjcareers.com/advicezone) for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site.</i>
Multicentric Validation of the Monocyte Assay for Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry
Authors: Sihem Tarfi, Véronique Harrivel, Florent Dumezy, Julien Guy, Mikael Roussel, Aguirre Mimoun, Pierre Fenaux, Nicolas Chapuis, Éric Solary, Dorothée Selimoglu-Buet, Orianne Wagner Ballon
Journal: Blood (2017)
Lowest perceived exertion in the late morning due to effects of the endogenous circadian system
Authors: Saurabh S Thosar, Maya Xolal Herzig, Sally A Roberts, Alec M Berman, Noal A Clemons, Andrew W McHill, Nicole P Bowles, Miki Morimoto, Matthew P Butler, Jonathan S Emens, Steven A Shea
Journal: British Journal of Sports Medicine (2018)

There are daily variations in the rate of perceived exertion (RPE)1 2 during exercise, with lower RPE in the beginning of the night compared with the early morning. We studied whether RPE is affected by the internal circadian system while controlling for any effects of behavioural patterns, including sleep, activity and meals.

Ten healthy adults (six females, aged 52±2 years (mean±SEM)) participated in a forced desynchrony protocol in dim light where all behaviours were evenly spread across the circadian cycle (figure 1A).3 After a normal night of sleep and baseline testing, participants underwent 10 recurring 5-hours 20-min of ‘behavioural cycles’ of 2-hours 40-min of sleep opportunities and 2-hours 40-min of standardised waking episodes.3 Approximately 1 hour after each sleep episode, participants performed mild intensity cycle ergometer exercise for …
Outcomes of metastatic chromophobe renal cell carcinoma (ChRCC) with sarcomatoid features (SF).
Authors: Yasser Ged, Andrea Knezevic, Yingbei Chen, Almedina Redzematovic, Maria Isabel Carlo, Chung-Han Lee, Darren R. Feldman, Sujata Patil, Robert J. Motzer, Martin Henner Voss
Journal: Journal of Clinical Oncology (2018)

678 Background: ChRCC makes up 5-10% of RCC subtypes and is generally thought to confer favorable prognosis. Presence of SF on histologic review can occur in any RCC subtype and is considered a hallmark of aggressive disease. We assessed outcomes in a cohort of patients (pts) with metastatic ChRCC and SF (sChRCC). Methods: Baseline clinical features and details on treatment were collected for pts with newly diagnosed metastatic sChRCC evaluated at Memorial Sloan Kettering Cancer Center (MSKCC) between 2002-17. Overall survival (OS) was calculated for all patients and time to treatment failure (TTF) for those who received first-line therapy at MSKCC. Next generation sequencing (NGS) with MSK-IMPACT was performed in a subset of pts. Results: 27 pts with newly diagnosed metastatic sChRCC were identified; other clinical features are summarized below ( table). 2 pts never received first line therapy based on poor performance status. 16 were treated at MSKCC and received a median of 2 lines of systemic therapy. First line agents included sunitinib (n = 6), pazopanib (n = 2), temsirolimus (n = 2), everolimus + bevacizumab (n = 2), sunitinib + gemcitabine (n = 2) and interferon alpha (n = 2) with median TTF of 2.1 months (0.9-14.5). Across the entire cohort (n = 27), median OS was 7.9 months (95% CI 4.2-11.2) with estimated 1 year OS rate of 25%. By comparison, a cohort of 67 pts with metastatic ChRCC lacking SF also treated at MSKCC 2002-17 achieved median OS of 38.1 months, (HR 4.6; 95% CI: 2.6-8.3; p &lt; 0.001). In the 6 sChRCC pts with NGS analysis, TP53 (n = 4), PTEN (n = 2) and CHEK2 (n = 2) were the most frequently altered genes. Conclusions: Outcome for pts with metastatic sChRCC was poor in contrast to pts with ChRCC lacking SF. The lack of benefit observed across various classes of systemic agents warrants study of underlying biology and novel agents. [Table: see text]
FONTAN PHENOTYPES HAVE SIGNATURE BIOMARKER EXPRESSION PROFILES
Authors: Anita Saraf, Christine De Stearcke, Jennifer Gerardin, Maria Pernetz, Georges Ephrem, Stacey Adjei, Staci Jennings, Naser Abdelhadi, Jonathan Kim, Fred Rodriguez, Wendy Book
Journal: Journal of the American College of Cardiology (2018)
The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis
Authors: Michael D. Deel, Katherine K. Slemmons, Ashley R. Hinson, Katia C. Genadry, Breanne A. Burgess, Lisa E.S. Crose, Nina Kuprasertkul, Kristianne M. Oristian, Rex C. Bentley, Corinne M. Linardic
Journal: Clinical Cancer Research (2018)

Purpose: Alveolar rhabdomyosarcoma (aRMS) is a childhood soft tissue sarcoma driven by the signature PAX3-FOXO1 (P3F) fusion gene. Five-year survival for aRMS is <50%, with no improvement in over 4 decades. Although the transcriptional coactivator TAZ is oncogenic in carcinomas, the role of TAZ in sarcomas is poorly understood. The aim of this study was to investigate the role of TAZ in P3F-aRMS tumorigenesis.Experimental Design: After determining from publicly available datasets that TAZ is upregulated in human aRMS transcriptomes, we evaluated whether TAZ is also upregulated in our myoblast-based model of P3F-initiated tumorigenesis, and performed IHC staining of 63 human aRMS samples from tissue microarrays. Using constitutive and inducible RNAi, we examined the impact of TAZ loss of function on aRMS oncogenic phenotypes in vitro and tumorigenesis in vivo Finally, we performed pharmacologic studies in aRMS cell lines using porphyrin compounds, which interfere with TAZ-TEAD transcriptional activity.Results: TAZ is upregulated in our P3F-initiated aRMS model, and aRMS cells and tumors have high nuclear TAZ expression. In vitro, TAZ suppression inhibits aRMS cell proliferation, induces apoptosis, supports myogenic differentiation, and reduces aRMS cell stemness. TAZ-deficient aRMS cells are enriched in G2-M phase of the cell cycle. In vivo, TAZ suppression attenuates aRMS xenograft tumor growth. Preclinical studies show decreased aRMS xenograft tumor growth with porphyrin compounds alone and in combination with vincristine.Conclusions: TAZ is oncogenic in aRMS sarcomagenesis. While P3F is currently not therapeutically tractable, targeting TAZ could be a promising novel approach in aRMS. Clin Cancer Res; 24(11); 2616-30. ©2018 AACR.
Re-intervention for stent–stone complex using intraductal cholangioscopy with electrohydraulic lithotripsy after multiple biliary metal stenting
Authors: Tadahisa Inoue, Yukiomi Nakade, Rena Kitano, Yuji Kobayashi, Norimitsu Ishii, Kiyoaki Ito, Masashi Yoneda
Journal: Endoscopy (2018)

A man in his 40s who had undergone right lobectomy for hepatocellular carcinoma, developed jaundice due to hilar biliary obstruction associated with recurrence of the cancer. Multiple metal stents were placed for the ventrolateral and dorsolateral segmental ducts, using a partial stent-in-stent method.
Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases.
Authors: Dexter Yak Seng Chan, Nicholas Syn, Cui Ting Neogh, Niam Sin Phua, Elya ., Jinghsan Ho, Raghav Sundar, Chee Seng Tan, Natalie Ngoi, Cheng Ean Chee, Asim Shabbir, Jimmy So, Wei-Peng Yong
Journal: Journal of Clinical Oncology (2018)

125 Background: Peritoneal metastasis is common in gastric cancer. It is difficult to treat and carries a grave prognosis. Studies have shown increased drug concentration in the peritoneal cavity when chemotherapy is administered intraperitoneally (IP). We had previously published early results on IP paclitaxel plus XELOX for such patients and now present our longer term data. Methods: Patients with unresectable and/or recurrent gastric adenocarcinoma with peritoneal dissemination and/or positive peritoneal washing cytology, not previously-treated or received prior systemic therapy &gt; 180 days ago and ECOG ≤2 are eligible. Patients were treated with 8 cycles of paclitaxel 40 mg/m 2 IP on days 1 and 8, oxaliplatin 100 mg/m 2 IV on day 1 and capecitabine 1000 mg/m 2 b.i.d. PO for 2 weeks followed by 1 week of rest. The primary endpoint is 1-year overall survival rate and the secondary endpoints are safety, response rate and peritoneal cytological response. Patients who subsequently have no distant metastases, with stable or reduced peritoneal disease and 2 consecutive negative peritoneal cytology would be eligible for conversion gastrectomy. Results: 34 patients have been enrolled and received at least one cycle at the time of reporting. Median no. of cycles is 8 (range: 1–8) and median follow-up is 30.2 months. Median OS is 16.4 months (IQR: 10.1–27.2) and 1-year survival rate is 64.9% (95% CI: 45.5%–78.9%). Of 30 evaluable patients, 1 achieved CR (3.3%), 6 (20.0%) achieved PR, 16 (53.3%) achieved SD and 7 (23.3%) experienced PD. Peritoneal cytology turned negative in 17 of 32 (53.1%) patients. Severe (grade ≥ 3) AE were neutropenia ( N= 7), febrile neutropenia ( N= 3), diarrhoea ( N= 3), hand-foot syndrome ( N= 2), bacterial peritonitis ( N= 2) and hypokalaemia ( N= 4) and tumour perforation ( N= 1). One death occurred due to neutropenic sepsis. 8 patients had conversion gastrectomy with no additional morbidity, with a 1-year survival of 87.5% with a median OS of 18.8 months. Conclusions: XELOX + IP paclitaxel appears to be a well-tolerated and active regimen in gastric cancer with peritoneal metastases, and may offer survival benefits. Finally, conversion gastrectomy may be considered in patients with favourable response. Clinical trial information: NCT01739894.
Low-grade gliomas quality of life: patients’ prospective
Authors: Laura Mullens, Jillian Maccoll, Francesco Vergani, Ranj Bhangoo, Richard Gullan, Lucy Brazil, Angela Swampillai, Ronald Beaney, Rob Urwin, Vicky Hurwitz, Liz Ford, Jess La, Keyoumars Ashkan
Journal: Neuro-Oncology (2018)

Management of low-grade gliomas is evolving. Increasing evidence suggests that radical treatment, including maximal surgical resection, radiotherapy and adjuvant chemotherapy provides patients with a better prognosis compared to a “watch and wait” policy. Despite advances in therapy, there is still limited data to guide health professionals how to improve the quality of patients’ survival. Previous studies for example, highlight decreased cognitive functioning of patients undergoing early radiotherapy (1). To identify the quality of life (QoL) needs of patients with low-grade gliomas within their first year of diagnosis. Apply holistic needs assessment to guide clinical practice towards improved good quality as well as quantity of survival. S35 patients at Kings College Hospital were radiologically diagnosed with a low-grade glioma in 2016. QoL questionnaires (Functional Assessment of Cancer Therapy- brain) were collected during their first year of diagnosis. 8/35 patients were not approached either due to severe cognitive impairment or logistics. All patients received a neuropsychology assessment, including WASI-II and WAIS-IV. Preliminary data is available on 10 patients at the time of this abstract: Poor energy levels- all 10 patients identified energy as a physical symptom that had concerned them in the past seven days. Limited support from friends- only 2/10 patients state they feel ‘very much’ close/supported by their friends. Worries about the future- 9/10 patients were worried that their condition will worsen. Abilities to work – only 1/10 patient was fulfilled with their work. Frustration – 9/10 patients state they had felt frustrated that they could not do things like they used to. Identifying the QoL needs will help to provide an individualized recovery strategy to help patients with low grade glioma. It will also provide a useful baseline to follow patients longitudinally over the course of their disease.
Public Health Perspectives on Depressive Disorders
Authors: Charles R. Conway
Journal: American Journal of Psychiatry (2018)

we may be able to extrapolate to psychoses more generally and eventually be able to move toward prevention and targeted treatments.Brockington argues that the art of clinical observation not only remains alive and well in psychiatry but also serves as the basis for allowing meaningful scientific discovery that will lead to improved outcomes and treatments for our patients.This book substantially adds to our ability to make progress in our field by drawing together a diverse literature, clinical expertise and experience, and the current basis of scientific knowledge.May it serve as the starting point for the scientific breakthroughs we need to move forward in the care and management of our psychiatric patients.
A NOVEL CLINICAL RISK MODEL FOR THE PREDICTION OF PROGRESSION OF ISCHEMIC MITRAL REGURGITATION IN PATIENTS WITH ADVANCED ISCHEMIC CARDIOMYOPATHY: A MULTIMODALITY STUDY
Authors: Natalie Ho, Kenya Kusunose, Nancy Obuchowski, Julijana Conic, Scott Flamm, Brian Griffin, Deborah Kwon
Journal: Journal of the American College of Cardiology (2018)
Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma
Authors: David G.P. van IJzendoorn, Stefan Sleijfer, Hans Gelderblom, Ferry A.L.M. Eskens, Geert J.L.H. van Leenders, Karoly Szuhai, Judith V.M.G. Bovée
Journal: Clinical Cancer Research (2018)

Purpose: Pseudomyogenic hemangioendothelioma (PHE) is an extremely rare locally aggressive neoplasm with endothelial differentiation, which often presents with multiple lesions. These tumors have characteristic SERPINE1-FOSB fusions. We report a 17 years old patient with advanced unresectable PHE with a durable complete remission to the multi-tyrosine kinase inhibitor telatinib. The aim of this study was to generate an in vitro model for PHE, to study the functional consequences of SERPINE1-FOSB in endothelial cells, and its interaction with telatinib, to biologically substantiate the complete response to telatinib.Experimental Design: As the fusion results in overexpression of a truncated form of FOSB, we overexpressed truncated FOSB in normal endothelial cells.Results: Truncated FOSB significantly affected tumor growth in three-dimensional (3D) on matrigel with increased and sustained sprouting. Moreover, truncated FOSB acted as an active transcription factor capable to regulate its own transcription, as well as to upregulate PDGFRA and FLT1 expression (four-fold). Telatinib decreased proliferation and tumor growth in 3D and induced apoptosis. As expected, telatinib blocked VEGF signaling as phosphorylation of ERK was abolished. Interestingly, in FOSB overexpressing cells, telatinib specifically affected PDGFRA, FLT1, and FLT4 signaling and downregulated SERPINE1, thereby affecting the self-regulation of the fusion gene.Conclusions: We provide a biological substantiation of a complete clinical remission that was seen in a patient with PHE, showing that telatinib indirectly interferes with the self-regulated expression of the fusion product. Thus, telatinib or any other currently available VEGFR1-4/PDGFRA inhibitor could be a highly specific treatment option for patients with multifocal unresectable PHE. Clin Cancer Res; 24(11); 2678-87. ©2018 AACR.
Delivery of low intensity/low frequency electric fields via clinical Deep Brain Stimulation electrodes has anti-proliferative effects on Glioblastoma multiforme cell lines
Authors: Joshua Branter, Maria de los Angeles Estevez-Cebrero, Richard Grundy, Surajit Basu, Stuart Smith
Journal: Neuro-Oncology (2018)

Phase III trials of Tumour Treating Fields (TTFields) have shown potentially positive results in both primary and recurrent adult Glioblastoma multiforme (GBM), giving hope that electric fields present a new treatment paradigm for brain tumours. Here we present investigations into the repurposing of deep brain stimulation (DBS) electrodes as a novel delivery method of therapeutic electric fields to high grade brain tumours as a localised, and internalised system. Medtronic DBS electrodes were inserted into cell culture flasks and delivered electric fields over a range of voltages and frequencies to a panel of primary, adult and paediatric GBM cell lines. Cell viability, cell count, cell cycle analyses, as well as combinational studies with an array of mitotic inhibitors were undertaken. DBS electric fields negatively affect cell counts and viabilities of GBM cells. Cell viability was reduced by up to 70% in U87, 74% in SF188, 71% in KNS42 and 45% in GIN-5 cell lines in a voltage-dependent manner The influence of frequency on cell viability is also demonstrated. Cell counts were undertaken of treated flasks and compared across all intensities. Cell cycle analysis performed via flow cytometry reveals that electrotreatment significantly increases the proportion of cells in G0 phase relative to control flasks in GBM cells. The effects of electrotreatment in combination with mitotic inhibitors are also explored. Implantable DBS electrodes have potential as a localised electric field based therapeutic strategy for the treatment of brain tumours. Electric fields delivered from DBS electrodes at significantly lower frequencies and intensities than those utilised by OptuneTM have profound anti-proliferative effects on GBM cell lines, causing measurable alterations in cell cycling. Impact: Implantable multiple DBS electrodes may address the compliance issues associated with Optune and provide a new modality for loco-regional brain tumour treatment.
HIGH-SENSITIVITY TROPONIN ASSAYS EXHIBIT PROHIBITIVELY HIGH FALSE POSITIVE RATES FOR MYOCARDIAL INFARCTION IN THE ELDERLY: FINDINGS FROM THE AGES REYKJAVIK STUDY
Authors: Tushar Acharya, Eric Leifer, Thor Aspelund, Gudny Eiriksdottir, Tamara Harris, Lenore Launer, Vilmundur Gudnason, Andrew Arai
Journal: Journal of the American College of Cardiology (2018)
LONG TERM OUTCOMES AFTER AORTIC VALVE SURGERY IN PATIENTS WITH ASYMPTOMATIC CHRONIC AORTIC REGURGITATION AND PRESERVED LEFT VENTRICULAR EJECTION FRACTION: ROLE OF PRE AND POST-OPERATIVE GLOBAL LONGITUDINAL STRAIN
Authors: Tamanna Khullar, Alaa Alashi, Amgad Mentias, Douglas Johnston, A. Gillinov, L. Leonardo Rodriguez, Lars Svensson, Zoran Popovic, Brian Griffin, Milind Y. Desai
Journal: Journal of the American College of Cardiology (2018)
REDUCTION IN TRIGLYCERIDE LEVELS ASSOCIATE WITH RAPID REGRESSION OF CORONARY ATHEROSCLEROSIS AFTER AN ACS
Authors: Jordan Andrews, Jelmer Jukema, Daisuke Shishikura, Satoshi Honda, Tracy Nguyen, Alex Janssan, Giuseppe DiGiovanni, Susan Kim, Constance Keyserling, Jean-Louis Dasseux, Stephen Nicholls
Journal: Journal of the American College of Cardiology (2018)